News

World Cancer Day – 4th Feb 2019

In 2019 in Australia, it is estimated there will be 12,681 combined new cases of leukaemia, lymphoma and myeloma

Blood cancers occur in both male and females when normal blood cell production is interrupted by the uncontrolled growth of an abnormal type of blood cell. There are three main types of blood cancer:

Lymphoma:
Lymphomas are blood cancers that affect the lymphatic system, part of the immune system which protects the body against disease and infection. Lymphomas occur when lymphocites (a type of white blood cell) undergo a malignant change and multiply in an uncontrolled way. The lymphoma cells then accumulate to form tumours in the lymph nodes, which are located throughout the body. There are two types of lymphoma; Hodgkin lymphoma and non-Hodgkin lymphoma, which can be distinguished by the specific lymphocites involved.

It is estimated 6423 new cases of lymphoma will be diagnosed in 2019, making Lymphoma the sixth most commonly diagnosed cancer in Australia.

Leukaemia:
Leukaemia starts in the bone marrow where developing blood cells (usually white cells) undergo a malignant change. These cells then crowd the marrow, affecting the body’s ability to produce normal blood cells.  In 2019, 4251 new cases of leukaemia are estimated to be diagnosed in Australia.

Myeloma:
Myeloma is a cancer that develops in plasma cells (a type of white cell) of the bone marrow. The usual role of plasma cells is to help fight infection. In 2019, it’s estimated that 2007 new cases of myeloma will be diagnosed.

Information from Cure Cancer  – Visit their site to learn more

Blood Cancer Research WA is collaborating with three sites to open more Clinical Trials in WA, so more West Australians have access to the latest treatment in blood cancer research.
Like and follow our Facebook page to keep up to date and click the “Donate” button on our website to contribute to this worthwhile foundation.

Solaris Cancer Care Annual Gala Dinner

Solaris Cancer Care Gala Fundraising Dinner
Saturday 9th February 6pm
– Hyatt Regency, Perth

Solaris Cancer Care’s annual fundraising dinner is set to be spectacular again with a raft of unique items to be won! Including, a Margaret River Pro Gold VIP experience, an amazing Rogaska crystal vase, a Wise Winery degustation lunch for eight and a beautiful pearl and diamond pendant from Willie Creek Pearls, to name a few.

For more information or to reserve a table for the 2019 event, contact info@solariscancercare.org.au or phone: 9384 3544

About Solaris Cancer Care

Solaris Cancer Care offer unconditional support to all people in Western Australia affected by cancer, including carers and family members, through all stages of the illness, including long term survivors and bereaved families.

Solaris Cancer Care’s programs cover important areas of wellbeing for individuals with cancer and their families.  In offering personalised support services, Solaris Cancer Care can personalise programs to integrate with chosen lifestyle and treatment regimes.

Solaris Cancer Care offers a holistic combination of:

  • Professional counselling
  • Evidence based education
  • Facilitated workshops
  • Regularly updated library
  • Seminars
  • Wellness coaching
  • Extended courses
  • Regular news updates
  • Home and hospital visits

To find out more about this wonderful foundation, visit https://solariscancercare.org.au/

 

Linear Clinical Research

Linear Clinical Research is a Phase I Clinical Trial unit, currently running close to 40 active trials. Located at Sir Charles Gairdner Hospital, Linear Clinical Research has the benefit of being close to consultants, with each patient being looked after by a dedicated, experienced medical team.

UNITY-NHL Trial now open at Sir Charles Gairdner Hospital

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Lymphomas are cancers of white blood cells that can be divided into indolent (slow growing) and aggressive (fast growing), though share common features that can be targeted by anti-cancer drugs.

This trial is for patients who have non-Hodgkin lymphoma which has returned after treatment. All patients will receive umbralisib, a tablet that targets an important pathway in the lymphoma called phosphatidylinositol-3-kinase delta (PI3K), which stops cancer cells from growing. Depending on the type of lymphoma, the some patients will also receive a lymphoma targeting antibody called ublituximab (intravenous) and/or a chemotherapy drug called bendamustine (intravenous).

The aim of the trial is to see whether the combinations of umbralisib, ublituximab, and bendamustine are effective in treating lymphoma.

This trial is now currently open at Hollywood Private Hospital and Sir Charles Gairdner Hospital. Details can be found at: UNITY NHL Trial

 

Clinical Trial Procedure

The majority of clinical trials that are being conducted are to research potential new treatments. Any treatment that is available on the market has undergone rigorous clinical trials to show through scientific research that the drug not only works but is also safe before it is approved to come on the market, a process that can take up to 15 years.

T-Cell Lymphomas

T-Cell Lymphomas are rare diseases, with about 450 Australians diagnosed each year. To add to the complexity of T-Cell Lymphomas, there are over 20 different types of the disease.

T-cells have the freedom to go wherever they wish, which is why we can see t-cell Lymphomas in different organs outside of lymph nodes. Sometimes in the skin, sometimes in the gut and sometimes in other organs that we don’t traditionally expect Lymphomas to be in. For this reason, t-cell lymphomas can be hard to find and often difficult to diagnose.

'Blood, Sweat and Tears of Joy' Educational Evening

‘Blood, Sweat and Tears of Joy’ Educational Evening

On Thursday 11th October, Blood Cancer Research Western Australia hosted an educational evening, ‘Blood, Sweat and Tears of Joy’ in conjunction with the Snowdome Foundation at the University of Western Australia. Hosted by Wendy Erber, Dean of UWA Medical School and Chaired by Professor David Joske, the evening provided an update on current research and trials.

Our very own Dr Chan Cheah presented during the evening, sharing details of the current progress in the WALCRE, which saw an increase in the number of trials open and available to patients, including two world first, first in human studies. Dr Cheah then went on to discuss the alliance between the trials units at Sir Charles Gairdner Hospital, Hollywood Private Hospital and Linear Clinical Research, offering a flexible platform to maximise the opportunities available to WA Blood Cancer patients to access potentially life-saving new drugs.

The attendees were also fortunate enough to have the opportunity to hear from Rita Zuks, a patient who has taken part in two clinical trials. Rita shared her experiences of the trials, which resulted in complete remissions on two consecutive studies for an aggressive lymphoma that had been refractory to many types of chemotherapy and a stem cell transplant.

Dr Chan Cheah then joined a panel alongside Dr Carolyn Grove, Dr Gavin Cull, Dr Brad Auguston and Rita Zuks to discuss current unmet needs in clinical research.

All round, the evening provided fantastic insights into the latest breakthroughs in finding a cure for Blood Cancers.

Two new trials open for patients with B-cell lymphoma and chronic lymphocytic leukemia

Two new phase I studies for patients with relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia have just opened at Linear Clinical Research.

Both explore new medicines with established mechanisms of action. TG-1701 is Btk inhibitor, and the bispecific engaging T-cell antibody mosentuzumab is a form of immunotherapy. They represent good options for eligible patients with B-cell lymphomas.

UNITY-NHL open at Hollywood Private Hospital

The UNITY-NHL study is now open at Hollywood Private Hospital. This phase IIB study is exploring the phosphatidylinositol-3-kinase delta inhibitor, umbralisib, either alone or in combination with an antibody against CD20 ublituximab in patients with  previously treated follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma. For more information visit the trial home page or speak to your Haematologist.

We will be opening the study at Sir Charles Gairdner Hospital in September to October 2018 for public patients.

ALLG HD10/ GHSG HD21 study open at Sir Charles Gairdner Hospital

The HD21 study, an Australiasian Leukaemia and Lymphoma Group collaboration with the German Hodgkin lymphoma stud group, is now open at SCGH.

This is the largest ever study to be performed in patients with advanced stage Hodgkin lymphoma, with a target recruitment of 1,600 patients in 10 countries. This is a randomized study comparing standard chemotherapy (BEACOPP escalated) to a new combination containing the antibody drug brentuximab vedotin (BreCADD). The question is whether this improves outcomes and reduces side effects in treatment-naive patients with  stage IIB – IV Hodgkin lymphoma.

For more information, visit https://www.bloodcancerwa.org.au/trial/hd10hd21-beacon/

or ask your Haematologist